secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001746473-22-000030
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics Q3 loss $30.6M; positive Phase 2a IPF data; $215M offering closed
--------------------------------------------------------------------------------

- Net loss of $30.6M in Q3 2022 vs $27.0M prior year; cash & investments $360.2M, funding to mid-2025.
- Positive Phase 2a data for bexotegrast in IPF: dose-dependent improvement in FVC, QLF, and biomarkers over 12 weeks.
- Closed public offering yielding $215.4M net proceeds to fund clinical programs and operations.
- Appointed Dr. Katharine Knobil to Board; oncology IND submission expected by end of 2022.
- DSMB reviews for INTEGRIS-IPF and INTEGRIS-PSC trials recommended continuation without modification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647322000030/0001746473-22-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647322000030/plrx-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001746473-22-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer